BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market

BrainStorm Cell Therapeutics has responded to its failure to win approval in the time-honored fashion. Yet, while the decision to lay off 30% of its staff is classical, the biotech’s reasoning is unusual. Rather than hunker down, BrainStorm is framing the action as a way to accelerate its journey back to the FDA.